Clinical trial
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
NCT00039104 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00039104 |
|---|---|
| Title | Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer |
| Official title | A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa™) and BMS-275291 (NSC#713763) in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | rebimastat, zoledronic acid, laboratory biomarker analysis |
| Enrollment | 50 |
| Start date | Apr 1, 2002 |
| Primary completion | Jan 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: